Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;7(2):676-82.
doi: 10.1007/s12072-012-9392-1. Epub 2012 Jul 27.

Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

Affiliations

Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

Tsung-Hsing Hung et al. Hepatol Int. 2013 Jun.

Abstract

Purpose: Diffuse infiltrative hepatocellular carcinoma (D-HCC) is an incurable disease with short survival time. Transarterial chemoembolization (TACE) was often used to alleviate patient's symptoms and reduce tumor burden. However, it remains unknown if the TACE benefits the survival of D-HCC patients.

Methods: A hospital-based retrospective study was conducted at a large referral hospital in Taiwan for a 9-year period (2000-2008).

Results: Of the 150 D-HCC patients, 106 patients were related to hepatitis B virus (HBV), 17 to hepatitis C virus (HCV), 3 to both HBV and HCV, and 24 not to HBV or HCV. Multivariate Cox regression analysis showed treatment strategy, serum alpha-fetoprotein level, model for end-stage liver disease (MELD) score, serum gamma glutamyl transferase, and serum lactic acid dehydrogenase were associated with survival time. Compared to supportive treatment, the adjusted hazard ratios of transarterial chemoembolization (TACE) and chemotherapy including oral or systemic chemotherapy were 0.383 (p < 0.001) and 0.711 (p = 0.289), respectively.

Conclusion: TACE is a preferred therapy for D-HCC patients.

Keywords: Diffuse infiltrative type; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Transarterial chemoembolization.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83 - PubMed
    1. Hepatogastroenterology. 2006 Mar-Apr;53(68):266-70 - PubMed
    1. Radiology. 1995 Oct;197(1):101-8 - PubMed
    1. Korean J Gastroenterol. 2007 Sep;50(3):176-82 - PubMed
    1. J Gastroenterol. 2010;45(1):105-12 - PubMed

LinkOut - more resources